Abstract Library

#3035 Large-Cell Neuroendocrine Carcinoma of the Lung in Elderly Patient: Case Report and Review of Literature

Introduction: Lung neuroendocrine tumors account for less than 25% of lung cancers.Which is a rare malignant tumor with an aggressive profile has often already affected lymph nodes at presentation and it is de novo metastatic in nearly 40% of cases.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Aliane H, Ghomari S,

Keywords: Large cell neuroendocrine carcinoma, Biopsy, Immunohistochemical staining, Chemosensitivity, Prognosis,

#2993 Proposal of New Imaging Criteria for Evaluating the Response of Liver Metastases to Systemic Treatments in Digestive Neuroendocrine Tumors (NET) as an Alternative to RECIST 1.1

Introduction: RECIST 1.1 criteria have been challenged for the evaluation of treatment response in NET.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: de Mestier L, Dromain C, Lamarca A, La Salvia A, Op de Beeck B,

Keywords: imaging criteria, response evaluation, CT scan,

#2849 PRRT Neuroendocrine Tumor Response Assessment Using Circulating Transcript Analysis: The NETest

Introduction: The absence of an accurate blood biomarker to predict and monitor PRRT is a key unmet need.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Bodei L

Authors: Bodei L, Kidd M, Singh A, van der Zwan W, Severi S,

Keywords: biomarker, PRRT, prediction, NETest, PPQ, CgA, personalized medicine,

#2217 Prognostic Impact of CHOI Response Criteria Compared to RECIST in Grade 1-2 Advanced Pancreatic Neuroendocrine Tumors (CRIPNET-GETNE Study-NCT02841865)

Introduction: Response Evaluation Criteria In Solid Tumors (RECIST) are not presumably the most optimal option for predicting the benefit of antiangiogenic drugs in neuroendocrine tumors (NETs), given that tumor shrinkage is not frequent, and qualitative changes in tumor tissues are to be expected.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Carmona-Bayonas A, Fernandez del Valle A, Solis M, Matos I, Garcia-Carbonero R,

Keywords: CHOI criteria, pancreatic neuroendocrine tumor, RECIST, response, survival,

#2083 Plasma Protein Kallikrein-14 Strongly Predicts Pronounced Chromogranin A (CgA) Response in Small Intestinal Neuroendocrine Tumor (NET) Patients after Somatostatin Analog (SSA) Treatment: The Nordic EXPLAIN Biomarker Study

Introduction: Predicting treatment response at an early stage in the treatment algorithm for NET is highly desirable.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Kjellman M

Authors: Kjellman M, Knigge u, Welin S, Grønbæk H, Thiis-Evensen E,

Keywords: Plasma Protein Biomarker,